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要　旨
２０１５年に日本で承認された新医療用原薬に対し、安定性試験の現状を調査した。我々は、２０１５年に安
定性試験の記述がある４７の新医療用原薬を特定した。長期保存試験としては、２７原薬が２５±２℃/６０±
５％相対湿度（RH）または３０±２℃/６５±５％RH の条件下で、８　 原薬が５±３℃で、１　 原薬が－１８℃
で、５　 原薬が－２０±５℃で、１　 原薬が－６５℃で、２　 原薬が－７０℃で、２　 原薬が黒塗りのため不明であり、
１　 原薬は半減期が短いため実施されなかった。光安定性試験では、２２原薬が安定で、１４原薬が光不安定
であり、１０原薬は記載がなく、１　 原薬は実施されなかった。光安定性試験で不安定であった原薬は、す
べて遮光保存とされた。これらのことから、２０１５年に承認された新医療用原薬は、ICH ガイドラインに
従って、適切に設定されていることがわかった。
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Abstract
To investigate the current status of stability testing in Japan, we identified ４７ new drug 
substances that had undergone stability testing in ２０１５.　Among these, ２７ were tested at ２５±２℃/６０
±５％ relative humidity（RH）or at ３０±２℃/６５±５％ RH, ８ were tested at ５±３℃, １ was tested at 
－１８℃, ５ were tested at －２０±５℃, １ was tested at －６５℃, ２ were tested at －７０℃, ２ were unknown 
because they were long-term testing items were left blank, and １ was not enforced due to its short 
half life. .　Photostability testing revealed ２２ new drug substances that were optically stable and 
１４ that were optically unstable, and whereas １０ new drug substances lacked a description and １ was 
not tested.　New drug substances that were unstable in photostability testing were stored in 
darkness.　The present data show adequate performance of new drug substances that were approved 
according to the ICH guidelines in Japan in ２０１５.
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原　著　論　文 
Introduction
Stability test results are an essential re-
quirement for New Drug Applications.　Ac-
cordingly, this requirement is discussed in the 
International Council on Harmonisation of 
Technical Requirements for Registration of 
Pharmaceuticals for Human Use（ICH）,１） and 
revisions of the guidelines for stability testing 
have been performed several times.
The guidelines for stability testing of new 
drug substances are listed in Table １ and com-
prise the following:
ICHQ１A（R２）states that the stability 
data package for new drug substances and 
drug products is sufficient for registration 
within the European Union, Japan, and the 
United States.１）
ICHQ１B states that the intrinsic photo-
stability characteristics of new drug sub-
stances and products should be evaluated to 
demonstrate that light exposure does not 
cause unacceptable changes.２）
ICHQ１C is an annex to the ICHQ１A
（R２）and recommends stability items to be 
submitted with new dosage forms by the origi-
nal applicant, after the original submission 
for a new drug substance or product.３）
ICHQ１D provides recommendations con-
cerning the application of bracketing and ma-
trixing in stability studies.４）
ICHQ１E provides recommendations on 
how to use stability data that is generated in 
accordance with the principles detailed in ICH
Q１A（R２）, and those can be used to inform 
re-test periods and shelf lives in applications 
for registration.５）　Additionally, this guideline 
describes when and how extrapolation can be 
used to inform a re-test periods for drug sub-
stances, and to determine the shelf life of drug 
products that extend beyond the period cov-
ered by“available data from the stability stud-
ies under long-term storage condition.”５）
According to ICHQ１A（R２）, New Drug 
Applications require long term and accelera-
tion studies to be included among stability 
tests.
Herein, we analyzed and discussed stabil-
ity testing data for drug substances that were 
approved by the Japanese government in ２０１５.
MATERIALS AND METHODS
We surveyed drugs that were approved 
from January to December ２０１５.　Informa-
tion was retrieved from data summaries
（Module ２ of Common Technical Document
（CTD）in the present system）that were sub-
mitted bas New Drug Applications, and from 
approval documents that describe specifica-
tions and test methods for drug substances.　
This information, especially from the quality 
section, is not all publicly available, although 
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Table １　Guidelines for stability testing of new drug substances
AbbreviationName of Guideline
ICHQ１A（R２）Stability Testing of New Drug Substances and Products
ICHQ１BStability Testing: Photostability Testing of New Drug Substances and Products,
ICHQ１CStability Testing for New Dosage Form
ICHQ１DBracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
ICHQ１EEvaluation of Stability Data,
Module ２ of the CTD and review reports are 
available on the internet.６）　Therefore, we do 
not disclose individual substance’ names herein.
RESULTS AND DISCUSSION
Classification  of  Approved  Drugs  by 
Stability Testing
A total of １０７ review reports were re-
trieved for １１５ drug substances that were ap-
proved from January to December ２０１５, and 
those excluded antiseptics for medical devices, 
in vivo diagnostics, and generic drugs.
Initially, we classified drugs according to 
whether they had been subjected to stability 
test and among １１５ drug substances ４７ drugs 
had stability testing and ６８ did not（Fig. １）.
The ６８ bulk drug substances that had not 
been subjected to stability testing were drugs 
with new administration routes, new indica-
tions, or new dosages, and were not tested for 
stability according to the approval matter par-
tial change application, which does not de-
mand stability testing.
Whereas, ４７ of １１５ new drug substances
（４１％）had stability testing data, this rate of 
stability testing was １０％ less than in ２０１４.７）
Hence, further analyses were performed 
the ４７ new drug substances with stability test-
ing data.
Long-term Testing
According to ICHQ１A（R２）,１） long-term 
testing for general new drug substances is per-
formed at ２５±２℃/６０±５％ relative humidity
（RH）or ３０±２℃/６５±５％RH.　However, for 
drug substances that are intended to be stored 
in a refrigerator, long-term testing is per-
formed at ５±３℃, and for drug substances that 
are intended to be stored in a freezer, long-
term testing is performed at －２０±５℃.　Ad-
ditionally, long-term testing for drug sub-
stances that are intended for storage at －２０℃ 
is performed on a case-by-case basis.
Long-term testing was performed at ２５±
２℃/６０±５％RH or ３０±２℃/６５±５％RH for ２７ 
new drug substances, at ５±３℃ for ８, at －１８℃ 
for １, at －２０±５℃ for ５, at －６５℃ for １, at －
７０℃ for ２, and at unknown temperatures for 
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Fig. 1　Classification of New Drug Substances according to whether they were 
　　　 subjected to stability testing
２, for which the data was concealed（Table 
２）.　One substance was not subjected to long 
term testing because its half life was too short.
Among the ４７ new drug substances, ２３, 
６, １, ２, ４ and １ had shelf lives or re-test peri-
ods of ＞ ３６, ２４, ２１, １, １２, ６ months, respective-
ly, and ９ had unknown shelf lives or re-test pe-
riods（Table ２）.
Moreover, １３ new drug substances that 
were scrutinized according to ICHQ１E５ had 
postponed expiration dates（Fig. ２）.
Extrapolation to extend the retest period 
or shelf life beyond the period covered by long-
term data can be proposed in the application, 
particularly if no significant change is ob-
served under accelerated conditions.　Specifi-
cally, the proposed retest period or shelf life 
can doubled at most, but should not be more 
increased than １２ months beyond the period 
covered by long-term data. As for Q１E appli-
cation items, a long-term test of １２２４ months 
was performed, and we consider the shelf lives 
or re-test periods of these new drug sub-
stances adequate.
Similarly long-term testing data indicates 
that the shelf lives or re-test periods of new 
drug substances are set and evaluated ade- 
quately.
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Table ２　Specific storage temperatures and conservation period in long-term testing
Number of New Drug ProductsShelf Life or Re-Test Period（month）Storage Condition
１３６
３０±２℃/６５±５％RH １１８ １１２
１Unknown*
９６０
２５±２℃/６０±５％RH
５４８
１３６
４２４
１１８
２１２
１Unknown*
２３６
５±３℃
２２４
１１２
１６
２Unknown*
１４８－１８℃
２６０－２０±５℃ ３Unknown*
１４８－６５℃
１３６－７０℃ １２１
２Unknown*Unknown*
１No enforcement**No enforcement**
 *: Blank entries are recorded as unknown.
**: Long-term testing was not performed because the half life was too  short.
Accelerated Testing
According to ICHQ１A（R２）,１） acceler-
ated testing for general new drug substances 
is performed at ４０±２℃/７５±５％ RH.　For 
drug substances that are intended for storage 
in a refrigerator, accelerated testing is per-
formed at ２５±２℃/６０±５％RH.
We found that accelerated testing was per-
formed at ４０±２℃/７５±５％RH for ２７, at ２５±
２℃/６０±５％ RH for ７, at ６℃ for １, at ５℃ for 
２ new drug substances, and the temperatures 
for ３ substances were concealed and were not 
listed for ７ substances.
Accelerated testing was performing for 
６ months at ４０℃ for all but one substance, 
which was tested for １２ months.　In addition, 
the duration of accelerated testing was con-
cealed for one substance.　All other sub-
stances were stable in accelerated tests.
Among accelerated tests that performed 
at ２５℃, one was performed for １２ months and 
the others performed for ６ months. One of sub-
stance, a genetic recombination, did not sat-
isfy the specification of ６ months. 
New drug substances that were subjected 
to acceleration testing at ６℃ for ６ months 
reportedly had remarkable resolution.　In 
contrast, new drug substances that were 
subjected to accelerated testing at ５℃ for ６ 
months were stable.
Three new drug substances that were 
tested at unknown temperatures included a ge-
netic recombination and ２ vaccines.　Because 
accelerated testing information is subjected to 
intellectual property laws, we were unable to 
show them.
Seven new drug substances with no re-
ported accelerated testing included a genetic re-
combination, extracts, a radioactive isotope, 
a vaccine, and drug master file registration 
products.　According to ICHQ１A（R２）,１） 
new drug substances that are stored in a 
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Fig. ２　Numbers of ICHQ１E applications
freezer do not require accelerated testing.　
Hence, these new drug substances do not have 
accelerated testing data.
Collectively, the results of accelerated 
testing indicate, that shelf lives or re-test pe-
riods of new drug substances are set and evalu-
ated adequately.
Photostability Testing
According to ICHQ１B,２）photostability 
testing of drug substances comprises forced 
degradation testing and confirmatory test- 
ing.　The purpose of forced degradation test-
ing is to evaluate overall photostability of the 
material for methods development purposes, 
and/or to elucidate degradation pathways.　
Hence, a variety of exposure conditions are 
used in forced degradation studies, sometimes 
producing decomposition products that are un-
likely to be formed under the conditions used 
for confirmatory studies.　This information 
facilitates the development and validation of 
analytical methods, and confirmatory studies 
are conducted to inform packaging and 
labeling.
Twenty-two new drug substances were 
optically stable and １４ were unstable. Al-
though １０substances did not have photostabil-
ity data, we assume that photostability test-
ing was performed（Fig. ３）.　Because most 
new drug substances are preserved under 
shaded condition, we conclude that the storage 
conditions are appropriate.
In conclusion, the present review included 
４７ new drug substances that were approved in 
Japan in ２０１５ according to ICH guidelines, 
and all performed adequately.
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Fig. ３　Itemization of photostability testing
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